Cardiology in Washington

Furuno Electric Co., Ltd. is a diversified manufacturer of marine navigation, positioning, and medical equipment. Primary business focuses on marine electronics for recreational boats, merchant marine, fishing vessels, and workboats, including fish finders, sonar systems, multi-beam sonars, marine radar, GPS/GNSS chart plotters, autopilots, and integrated navigation displays. The company also manufactures GPS/GNSS receiver chips and modules for positioning and timing applications, including 5G network infrastructure. In the medical segment, Furuno produces clinical chemistry analyzers and ultrasound bone densitometers for diagnostic and monitoring applications. The company provides navigational equipment training and coastal monitoring systems. Furuno operates with advanced capabilities in GNSS timing technology, autonomous navigation solutions, cyber security, and remote monitoring platforms. The organization serves global maritime markets and has expanded into industrial positioning and healthcare diagnostics. Products meet international maritime standards and regulatory requirements for marine equipment.

D. E. Hokanson, Inc. designs, manufactures and sells noninvasive diagnostic instruments for vascular assessment and peripheral vascular disease diagnosis. Founded in 1973, the company specializes in blood flow measurement and vascular testing equipment, including vascular Dopplers, plethysmographs, cuff inflators, and vascular cuffs. Products serve vascular specialists, primary care physicians, cardiologists, endocrinologists, wound care professionals, and clinical researchers. The company manufactures all products in the USA and offers a comprehensive 5-year warranty. Hokanson instruments utilize pulse wave Doppler, continuous wave Doppler, and plethysmography technologies to facilitate noninvasive peripheral vascular physiological testing, ankle-brachial index (ABI) measurement, toe pressure assessment, and venous reflux evaluation. Applications include peripheral artery disease (PAD) screening, diabetes-related vascular complications, wound care assessment, and vascular research.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in photodisinfection (antimicrobial photodynamic therapy) technologies for infection prevention and treatment. The company's patented platform uses non-thermal laser light activation with photosensitive agents to destroy bacteria, viruses, yeasts, fungi, and associated virulence factors within minutes—without generating antimicrobial resistance. The lead product, Steriwave, is a rapid nasal decolonization therapy that eliminates broad-spectrum pathogens including methicillin-resistant Staphylococcus aureus (MRSA), Candida auris, and SARS-CoV-2 from the nasal cavity, significantly reducing healthcare-associated infections (HAIs) and surgical site infections (SSIs). Clinical evidence from major Canadian hospitals demonstrates up to 84% reduction in postoperative infection rates and 39.5% pneumonia reduction in ICU settings. Photodisinfection offers advantages over traditional antibiotics including immediate pathogen destruction, potent anti-inflammatory effects, and safety for patient outcomes. The company maintains a pipeline of investigational products addressing chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection to prevent ventilator-associated pneumonia, and topical antiviral therapies for upper respiratory tract infections. Ondine's technology platform is designed for straightforward clinical adoption with minimal workflow disruption and no complex compliance barriers. Note: Products are not currently for sale in the United States. The company operates as a specialized biomedical device and therapeutic solutions provider focused on addressing antimicrobial resistance through innovative light-activated infection control mechanisms.